Donald A. Bergstrom - 24 Mar 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
24 Mar 2022
Net transactions value
-$258,800
Form type
4
Filing time
28 Mar 2022, 20:11:22 UTC
Previous filing
11 Mar 2022
Next filing
31 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $41,200 +10,000 +11% $4.12 104,926 24 Mar 2022 Direct F1, F2
transaction RLAY Common Stock Sale $300,000 -10,000 -9.5% $30.00 94,926 24 Mar 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -10,000 -4.4% $0.000000 217,456 24 Mar 2022 Common Stock 10,000 $4.12 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2 Includes 93,387 shares underlying restricted stock units.
F3 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.